PortfoliosLab logoPortfoliosLab logo
ISIN
US9553061055
CUSIP
955306105
IPO Date
Jan 13, 1978

Highlights

Market Cap
$24.35B
Enterprise Value
$24.17B
EPS (TTM)
$7.47
PE Ratio
45.03
Total Revenue (TTM)
$3.22B
Gross Profit (TTM)
$1.17B
EBITDA (TTM)
$799.00M
Year Range
$206.80 - $336.82
Target Price
$303.33
ROA (TTM)
13.21%
ROE (TTM)
18.15%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

WST Performance Chart

West Pharmaceutical Services, Inc. (WST) is up 22.5% since the beginning of the year. At $336 per share, WST is currently trading at its 52-week high. Investors who bought $1,000 worth of WST shares 5 years ago would now be looking at an investment worth $948.


Loading charts...

S&P 500 Index

Returns By Period

West Pharmaceutical Services, Inc. (WST) has returned 22.47% so far this year and 55.74% over the past 12 months. Looking at the last ten years, WST has achieved an annualized return of 16.97%, outperforming the S&P 500 Index benchmark, which averaged 13.71% per year.


West Pharmaceutical Services, Inc.

1D
2.03%
1M
6.31%
YTD
22.47%
6M
21.43%
1Y
55.74%
3Y*
-2.59%
5Y*
-1.07%
10Y*
16.97%

Benchmark (S&P 500 Index)

1D
-1.44%
1M
-1.45%
YTD
7.60%
6M
6.59%
1Y
22.24%
3Y*
19.20%
5Y*
11.54%
10Y*
13.71%
*Multi-year figures are annualized to reflect compound growth (CAGR)

WST Monthly Returns History

Based on dividend-adjusted daily data since Jan 5, 1988, WST's average daily return is +0.06%, while the average monthly return is +1.25%. At this rate, an investment would double in approximately 4.6 years.

Historically, 60% of months were positive and 40% were negative. The best month was Apr 2020 with a return of +24.4%, while the worst month was Sep 2004 at -47.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, WST closed higher 47% of trading days. The best single day was Jul 24, 2025 with a return of +22.8%, while the worst single day was Sep 30, 2004 at -49.3%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-15.92%10.05%-1.45%18.82%8.47%4.21%22.47%
20254.27%-31.93%-3.64%-5.53%-0.21%3.77%9.44%3.21%6.23%7.52%-1.63%-0.76%-15.73%
20246.00%-3.93%10.42%-9.61%-7.29%-0.61%-6.99%2.44%-4.29%2.59%5.83%0.58%-6.75%
202312.93%19.36%9.29%4.32%-7.37%14.30%-3.72%10.56%-7.79%-15.17%10.27%0.39%49.97%
2022-16.12%-1.56%6.10%-23.25%-1.49%-2.58%13.69%-13.64%-17.06%-6.49%2.07%0.29%-49.70%
20215.77%-6.29%0.40%16.65%5.78%3.34%14.71%9.69%-6.00%1.26%3.02%5.95%65.88%

Benchmark Metrics

West Pharmaceutical Services, Inc. has an annualized alpha of 9.41%, beta of 0.64, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since January 05, 1988.

  • This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (87.64%) than losses (73.41%) - typical of diversified or defensive assets.
  • Beta of 0.64 may look defensive, but with R2 of 0.15 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.15 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
9.41%
Beta
0.64
0.15
Upside Capture
87.64%
Downside Capture
73.41%

Return for Risk

Risk / Return Rank

WST ranks 79 for risk / return — better than 79% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


WST Risk / Return Rank: 7979
Overall Rank
WST Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
WST Sortino Ratio Rank: 8383
Sortino Ratio Rank
WST Omega Ratio Rank: 8080
Omega Ratio Rank
WST Calmar Ratio Rank: 7878
Calmar Ratio Rank
WST Martin Ratio Rank: 7575
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for West Pharmaceutical Services, Inc. (WST) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


WSTBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-0.42

Sortino ratioReturn per unit of downside risk

+0.03

Omega ratioGain probability vs. loss probability

1.30

1.32

-0.03

Calmar ratioReturn relative to maximum drawdown

2.27

2.46

-0.19

Martin ratioReturn relative to average drawdown

4.55

10.92

-6.37

Dividends

Dividend History

West Pharmaceutical Services, Inc. provided a 0.26% dividend yield over the last twelve months, with an annual payout of $0.87 per share. The company has been increasing its dividends for 20 consecutive years.


0.20%0.30%0.40%0.50%0.60%0.70%$0.00$0.20$0.40$0.60$0.8020152016201720182019202020212022202320242025
Dividends
Dividend Yield
PeriodTTM20252024202320222021202020192018201720162015
Dividend$0.87$0.85$0.81$0.77$0.73$0.69$0.65$0.61$0.57$0.53$0.49$0.45

Dividend yield

0.26%0.31%0.25%0.22%0.31%0.15%0.23%0.41%0.58%0.54%0.58%0.75%

Monthly Dividends

The table displays the monthly dividend distributions for West Pharmaceutical Services, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.22$0.00$0.00$0.22$0.00$0.00$0.44
2025$0.00$0.21$0.00$0.21$0.00$0.00$0.21$0.00$0.00$0.00$0.22$0.00$0.85
2024$0.20$0.00$0.00$0.20$0.00$0.00$0.20$0.00$0.00$0.00$0.21$0.00$0.81
2023$0.19$0.00$0.00$0.19$0.00$0.00$0.19$0.00$0.00$0.00$0.20$0.00$0.77
2022$0.18$0.00$0.00$0.18$0.00$0.00$0.18$0.00$0.00$0.00$0.19$0.00$0.73
2021$0.17$0.00$0.00$0.17$0.00$0.00$0.17$0.00$0.00$0.00$0.18$0.00$0.69

Dividend Yield & Payout


Dividend Yield

West Pharmaceutical Services, Inc. has a dividend yield of 0.26%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.

Payout Ratio

West Pharmaceutical Services, Inc. has a payout ratio of 11.39%, which is below the market average. This means West Pharmaceutical Services, Inc. returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the West Pharmaceutical Services, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the West Pharmaceutical Services, Inc. was 59.29%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current West Pharmaceutical Services, Inc. drawdown is 27.77%.


Related event

Drawdown

Fall

Recovery

Underwater

2025 selloff2025
-59.29%Apr 2025
3y 3mo
4y 5moDec 2021 - now
Dot-com crash2000–2002
-54.74%Oct 2002
3y 3mo1y 1mo
4y 4moJul 1999 - Dec 2003
2004 bear market2004
-52.13%Oct 2004
3mo 22d1y 10mo
2y 2moJul 2004 - Sep 2006
1990 bear market1990
-50.49%Nov 1990
1y 1mo1y 5mo
2y 7moOct 1989 - May 1992
Financial crisis2007–2009
-45.12%Mar 2009
5mo 18d3y 3mo
3y 8moSep 2008 - Jun 2012

Drawdown Indicators


WSTBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-59.29%

-56.78%

-2.51%

Max Drawdown (1Y)

Largest decline over 1 year

-24.70%

-9.10%

-15.60%

Max Drawdown (3Y)

Largest decline over 3 years

-53.79%

-18.90%

-34.89%

Max Drawdown (5Y)

Largest decline over 5 years

-59.29%

-25.43%

-33.86%

Max Drawdown (10Y)

Largest decline over 10 years

-59.29%

-33.92%

-25.37%

Current Drawdown

Current decline from peak

-27.77%

-3.21%

-24.56%

Average Drawdown

Average peak-to-trough decline

-16.89%

-10.71%

-6.18%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.30%

2.04%

+10.26%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of West Pharmaceutical Services, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how West Pharmaceutical Services, Inc. is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for WST, comparing it with other companies in the Medical Instruments & Supplies industry. Currently, WST has a P/E ratio of 45.0. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for WST relative to other companies in the Medical Instruments & Supplies industry. Currently, WST has a P/S ratio of 7.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for WST in comparison with other companies in the Medical Instruments & Supplies industry. Currently, WST has a P/B value of 8.1. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with WST

Add West Pharmaceutical Services, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with WST